Inozyme Pharma, Inc.

Inozyme Pharma, Inc. priced its initial public offering on Jul 24, 2020 at $16.00 per share, raising $112M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $357M. BofA Securities was lead-left underwriter, joined by TD Cowen, Piper Sandler and Wedbush. WilmerHale advised the company and A&O Shearman advised the underwriters.

Inozyme Pharma, Inc. is a rare disease biopharmaceutical company developing therapeutics for diseases of abnormal mineralization affecting the vasculature, soft tissue and skeleton. Its lead candidate, INZ-701, is a recombinant fusion protein for ENPP1 and ABCC6 deficiencies.

Status

IPO

Exchange

Nasdaq Global Select

Priced

Jul 24, 2020

IPO price

$16.00

Raised

$112M

Market cap at IPO price

$357M

First filed

Jul 2, 2020

Underwriters

BofA Securities, TD Cowen, Piper Sandler and Wedbush

Company counsel

WilmerHale

Underwriters' counsel

A&O Shearman

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.